82 / 164
212
control in type 2 diabetes mellitus. N Engl J Med 2010;
362:1575–1585.
29. Zhang Y, Zhang X, Liu L, Zanchetti A. Is a systolic blood
pressure target
<
140mmHg indicated in all hypertensives?
Subgroup analyses of findings from the randomized FEVER
trial” European Heart Journal 2011; 32: 1500–1508.
30. Heart Outcomes Prevention Evaluation Study Investigators.
Effects of ramipril on cardiovascular and microvascular
outcomes in people with diabetes mellitus: results of the
HOPE study and MICRO-HOPE sub-study. Lancet 2000; 355:
253–59.
31. Mancia G, Schumacher H, Redon J, Verdecchia P, Schmieder
R, Jennings G, et al. Blood pressure targets recommended
by guidelines and incidence of cardiovascular and renal
events in the Ongoing Telmisartan Alone and in Combination
With Ramipril Global EndpointTrial Circulation 2011;124:
1727-36 201.
32. Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue Jet
al (ONTARGET Investigators). Safety and efficacy of low blood
pressures among patients with diabetes: subgroup analyses
from the ONTARGET J Am Coll Cardiol. 2012; 59:74-83.
33. Cederholm J, Gudbjornsdottir S, Eliasson B, Zethelius B,
Eeg-Olofsson K, Nilsson PM. Blood pressure and risk of
cardiovascular disease in type 2 diabetes: further findings
from the Swedish National Diabetes Register. J Hypertens
2012; 30:2020–30.
34. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek
JW et al. The effects of dietary protein restriction and blood-
pressure control on the progression of chronic renal disease.
Modification ofDiet in Renal Disease Study Group. N Engl J
Med 1994; 330:877–884).
35. Agodoa L, Baigent C, Black H, Boissel JP, Brenner B, Brown M,
et al on behalf of Blood Pressure Lowering Treatment Trialists’
Collaboration. Effects of different blood pressure-lowering
regimens on major cardiovascular events in individuals
with and without diabetes mellitus: results of prospectively
designed overviews of randomized trials. Arch Intern Med.
2005;165:1410-19.
[REV. MED. CLIN. CONDES - 2016; 27(2) 204-212]